Details of the Drug Formulations

General Information of Drug (ID: DMD2NV7)

Drug Name

Pindolol Drug Info

Synonyms

Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1] , [2]

Therapeutic Class

Antihypertensive Agents

Cross-matching ID

PubChem CID: 4828
ChEBI ID: CHEBI:8214
CAS Number: 13523-86-9
TTD ID: D0F2PO
VARIDT ID: DR00610
ACDINA ID: D00533

Full List of Drug Formulations Containing This Drug

Pindolol 10 mg tablet

Company	Formulation ID	FDA Description
Carilion Materials Management; Mylan Pharamceuticals	F17274	Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Starch, corn
Cadila Healthcare; Zydus Pharmaceuticals	F17275	Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Starch, pregelatinized corn
ANI Pharmaceuticals	F17273	Magnesium stearate; Silicon dioxide; Microcrystalline cellulose; Starch, corn
Sun Pharmaceutical Industries	F17272	Anhydrous lactose; Magnesium stearate; Crospovidone (15 mpa.s at 5%); Microcrystalline cellulose; Starch, corn
Nostrum Laboratories	F17276	Lactose monohydrate; Magnesium stearate; Cellulose, microcrystalline; Colloidal silicon dioxide; Sodium starch glycolate type a corn; Starch, corn
------------------------------------------------------------------------------------

Pindolol 5 mg tablet

Company	Formulation ID	FDA Description
Mylan Pharamceuticals	F17279	Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Starch, corn
Cadila Healthcare; Zydus Pharmaceuticals	F17280	Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Starch, pregelatinized corn
Carilion Materials Management	F17281	Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Silicon dioxide; Microcrystalline cellulose; Starch, corn
Nostrum Laboratories	F17282	Lactose monohydrate; Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline; Sodium starch glycolate type a corn; Starch, corn
ANI Pharmaceuticals	F17278	Magnesium stearate; Silicon dioxide; Microcrystalline cellulose; Starch, corn
Sun Pharmaceutical Industries	F17277	Anhydrous lactose; Magnesium stearate; Crospovidone (15 mpa.s at 5%); Microcrystalline cellulose; Starch, corn
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Formulation(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 91).
2	Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997 Nov 1;157(9):1245-54.